BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25681082)

  • 1. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening.
    Chien YH; Goldstein JL; Hwu WL; Smith PB; Lee NC; Chiang SC; Tolun AA; Zhang H; Vaisnins AE; Millington DS; Kishnani PS; Young SP
    JIMD Rep; 2015; 19():67-73. PubMed ID: 25681082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
    Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
    Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
    Young SP; Zhang H; Corzo D; Thurberg BL; Bali D; Kishnani PS; Millington DS
    Genet Med; 2009 Jul; 11(7):536-41. PubMed ID: 19521244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort.
    Piraud M; Pettazzoni M; de Antonio M; Vianey-Saban C; Froissart R; Chabrol B; Young S; Laforêt P;
    Mol Genet Metab Rep; 2020 Jun; 23():100583. PubMed ID: 32382504
    [No Abstract]   [Full Text] [Related]  

  • 6. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
    Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
    Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of newborn screening for Pompe disease in Japan.
    Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
    Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
    An Y; Young SP; Kishnani PS; Millington DS; Amalfitano A; Corz D; Chen YT
    Mol Genet Metab; 2005 Aug; 85(4):247-54. PubMed ID: 15886040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.
    Lin N; Huang J; Violante S; Orsini JJ; Caggana M; Hughes EE; Stevens C; DiAntonio L; Chieh Liao H; Hong X; Ghomashchi F; Babu Kumar A; Zhou H; Kornreich R; Wasserstein M; Gelb MH; Yu C
    Clin Chem; 2017 Apr; 63(4):842-851. PubMed ID: 28196920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease.
    Liao HC; Chan MJ; Yang CF; Chiang CC; Niu DM; Huang CK; Gelb MH
    Clin Chem; 2017 Jul; 63(7):1271-1277. PubMed ID: 28450385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease.
    Davids L; Sun Y; Moore RH; Lisi E; Wittenauer A; Wilcox WR; Ali N
    Mol Genet Metab; 2021; 134(1-2):20-28. PubMed ID: 34602357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
    Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
    Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn Screening for Pompe Disease: Pennsylvania Experience.
    Ficicioglu C; Ahrens-Nicklas RC; Barch J; Cuddapah SR; DiBoscio BS; DiPerna JC; Gordon PL; Henderson N; Menello C; Luongo N; Ortiz D; Xiao R
    Int J Neonatal Screen; 2020 Nov; 6(4):. PubMed ID: 33202836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
    Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
    Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with the Urinary Tetrasaccharide Metabolite for Pompe Disease in the Diagnostic Laboratory.
    Saville JT; Fuller M
    Metabolites; 2021 Jul; 11(7):. PubMed ID: 34357340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Timely Needs for Infantile Onset Pompe Disease Newborn Screening-Practice in Taiwan.
    Chiang SC; Chien YH; Chang KL; Lee NC; Hwu WL
    Int J Neonatal Screen; 2020 Jun; 6(2):30. PubMed ID: 33073026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in late and lost: Pediatricians' role in following Pompe disease identified by newborn screening.
    Pillai NR; Fabie NAV; Kaye TV; Rosendahl SD; Ahmed A; Hietala AD; Jorgenson AB; Lanpher BC; Whitley CB
    Mol Genet Metab; 2023; 140(1-2):107633. PubMed ID: 37414610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
    Fukuhara Y; Fuji N; Yamazaki N; Hirakiyama A; Kamioka T; Seo JH; Mashima R; Kosuga M; Okuyama T
    Mol Genet Metab Rep; 2018 Mar; 14():3-9. PubMed ID: 29124014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review.
    Schoser B; Raben N; Varfaj F; Walzer M; Toscano A
    Mol Genet Metab Rep; 2024 Jun; 39():101085. PubMed ID: 38698877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The decision-making levels of urine tetrasaccharide for the diagnosis of Pompe disease in the Turkish population.
    Canbay E; Vural M; Kalkan Uçar S; Sezer ED; Karasoy H; Yüceyar AN; Çoker M; Sözmen EY
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):391-395. PubMed ID: 32069240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.